Enlivex Therapeutics Ltd's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Enlivex Therapeutics Ltd in the fourth quarter 2025?
Enlivex Therapeutics Ltd achieved a return on average equity (ROE) of 125.87 % in its fourth quarter 2025, this is above ENLV's average return on equity of -80.25%.
Enlivex Therapeutics Ltd shareholder's equity over the 12 months ending in its fourth quarter 2025 are valued at $977 million

ROE has advanced compared to -1.68% in the third quarter 2025, due to net income growth.

Within the Major Pharmaceutical Preparations industry 13 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2025 from to 120.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Jun 30 2024) II. Quarter
Y / Y Equity Change	8102.76 %	6674.55 %	-36.66 %	-31.44 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	1,230	-8	-13	-40	-36
Return On Equity (TTM)	125.87 %	-1.68 %	-54.69 %	-154.6 %	-129.29 %
ENLV's Total Ranking	# 120	#	#	#	#
Equity (TTM) in Millions	1,935	1,935	19	21	24
Seq. Equity Change	0 %	10055.08 %	-7.63 %	-12.56 %	-17.41 %
Seq. Net Income Change	-	-	-	-	-

Back to ENLV Management Effectiveness >> ENLV's 5 Years Annual ROE >> Compare ENLV ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 14
Sector	# 32
Overall	# 120

Return On Equity Statistics
High	Average	Low
85.68 %	-80.25 %	-570.18 %
(Dec 31 2015)		(Dec 31 2016)

ENLV Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	1,935	24	30	57	85
Y / Y Equity Change	8102.76 %	-21.59 %	-47.07 %	-33.16 %	139.63 %
Net Income in Millions	1,236	-15	-29	-31	-14
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	63.85 %	-63.65 %	-96.62 %	-54.64 %	-17.01 %

Back to ENLV Management Effectiveness >> ENLV's 5 Years Annual ROE >> Compare ENLV ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 63.85 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ENLV's' Return on Equity at Yahoo Finance
ENLV's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ENLV's Competitors
Subscribers only: Roe for Enlivex Therapeutics Ltd's Suppliers
Subscribers only: Return On Equity for ENLV's Customers

Companies with similar Return On Equity at Dec 31 2025, within Healthcare Sector	ROE
Traws Pharma inc	273.56 %
Scisparc Ltd	244.10 %
Rigel Pharmaceuticals Inc	240.83 %
Icecure Medical Ltd	166.36 %
Capforce Inc	157.18 %
Advanced Biomed Inc.	142.91 %
Check Cap Ltd	120.45 %
Medpace Holdings Inc	118.82 %
Tg Therapeutics Inc	101.12 %
Eli Lilly And Company	97.61 %
Amgen Inc	96.65 %
Halozyme Therapeutics Inc	92.67 %
Earth Science Tech Inc	82.09 %
Exelixis Inc	81.25 %
Elite Pharmaceuticals Inc	80.28 %
Zevra Therapeutics Inc	74.63 %
3m Company	71.32 %
Entera Bio Ltd	70.43 %
Aurinia Pharmaceuticals Inc	70.37 %
Idexx Laboratories Inc	69.78 %
Alnylam Pharmaceuticals Inc	69.25 %
Enlivex Therapeutics Ltd	63.85 %
Dariohealth Corp	59.48 %
Nrc Health	58.51 %
Zoetis Inc	56.31 %
Alpha Tau Medical Ltd	55.29 %
Transmedics Group Inc	53.88 %
Pulmatrix Inc	53.50 %
Abeona Therapeutics Inc	53.18 %
Medinotec Inc	52.76 %

Date modified: 2026-07-09T17:12:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.